Methods for treating heart failure using glucagon receptor antagonistic antibodies
AssigneeREMD Biotherapeutics, Inc.
InventorHai Yan
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating or preventing heart failure using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing heart failure (e.g., post-myocardial infarction heart failure), diabetic cardiomyopathy heart failure), and lateral ventricular (LV) remodeling, using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor.
Claims11
A method for treating heart failure in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an isolated antagonistic antigen binding protein that specifically binds to the human glucagon receptor, wherein the antagonistic antigen binding protein is selected from:
- (a) a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain variable region of SEQ ID NO:
- 2 and the amino acid sequence encoding the light chain variable region of SEQ ID NO:
- 3;
- (b) a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain variable region of SEQ ID NO:
- 4 and the amino acid sequence encoding the light chain variable region of SEQ ID NO:
- 5;
- (c) a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain variable region of SEQ ID NO:
- 6 and the amino acid sequence encoding the light chain variable region of SEQ ID NO:
- 7;
- (d) a human anti-GCGR antibody which comprises a heavy chain variable region having the amino acid sequence selected from the group consisting of SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, and SEQ ID NO:
- 28;
- and a human anti-GCGR antibody which comprises a light chain variable region having the amino acid sequence selected from the group consisting of SEQ ID NO:
- 29, SEQ ID NO:
- 30, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44, SEQ ID NO:
- 45, SEQ ID NO:
- 46, and SEQ ID NO:
- 47;
- or (e) a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain variable region of SEQ ID NO:
- 28 and the amino acid sequence encoding the light chain variable region of SEQ ID NO:
- 47.
A method of treating lateral ventricular (LV) remodeling comprising administration of a therapeutically effective amount of an isolated antagonistic antigen binding protein that specifically binds to the human glucagon receptor, wherein the antagonistic antigen binding protein is selected from:
- (a) a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain variable region of SEQ ID NO:
- 2 and the amino acid sequence encoding the light chain variable region of SEQ ID NO:
- 3;
- (b) a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain variable region of SEQ ID NO:
- 4 and the amino acid sequence encoding the light chain variable region of SEQ ID NO:
- 5;
- (c) a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain variable region of SEQ ID NO:
- 6 and the amino acid sequence encoding the light chain variable region of SEQ ID NO:
- 7;
- (d) a human anti-GCGR antibody which comprises a heavy chain variable region having the amino acid sequence selected from the group consisting of SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, and SEQ ID NO:
- 28;
- and a human anti-GCGR antibody which comprises a light chain variable region having the amino acid sequence selected from the group consisting of SEQ ID NO:
- 29, SEQ ID NO:
- 30, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44, SEQ ID NO:
- 45, SEQ ID NO:
- 46, and SEQ ID NO:
- 47;
- or (e) a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain variable region of SEQ ID NO:
- 28 and the amino acid sequence encoding the light chain variable region of SEQ ID NO:
- 47.
Dependencies are inferred from the claim text.